Carroll: Major and minor fusion partners listed; target-able. RNA on 8-15 gene signature (on QuantStudio 12K, TaqMan Array card) #ASCO15
9:39am May 30th 2015 via Hootsuite
Carroll: Ph-like B-ALL: gene expression similar but no BCR-ABL1 fusion. 3x more likely to die (plots shown); 27% in young adults #ASCO15
9:38am May 30th 2015 via Hootsuite
Carroll: Methylation may provide clues for Wnt activation http://t.co/7BEQpot6Ps #ASCO15
9:36am May 30th 2015 via Hootsuite
Carroll:Tumors defined by sentinel genetic lesions may not share oncogenic drivers. Rhabdomyosarcoma http://t.co/y7VkfobHwo #ASCO15
9:34am May 30th 2015 via Hootsuite
Carroll: Another example, Ewings sarcoma. Tirode '14 fig http://t.co/IX0hSgMc2c #ASCO15
9:33am May 30th 2015 via Hootsuite
Carroll: Gave 4 pediatric tumors that follow these rules; and many wished for. Neuroblastoma figure from '13 Pugh ttp://ow.ly/NDScC #ASCO15
9:32am May 30th 2015 via Hootsuite
Carroll: Pediatric cancer - 8-10 mutations, driver mutations only need 0.4% growth advantage. 50% of discovery is passenger. #ASCO15
9:30am May 30th 2015 via Hootsuite
Carroll: (Prev quote from Nov '14 NYT aritcle) The 'perfect target' - somatic mutation, driver, and shared across types. #ASCO15
9:29am May 30th 2015 via Hootsuite
Carroll:'The claims for genomics in the '90s sounds like... predictions made in the '50's for flying cars and anti-gravity devices' #ASCO15
9:28am May 30th 2015 via Hootsuite
William Carroll (NYU Langone) "State-of-the-Art Discovery with Tumor Profiling in Pediatric Oncology" #ASCO15
9:27am May 30th 2015 via Hootsuite
Parsons:Q:Opening up data? A:Currently dbGAP. Vast majority of participants consent. #ASCO15
9:24am May 30th 2015 via Hootsuite
Parsons: The best 'test' remains to be proven. 'Huge interpretation challenge'. Long list of credits, co-PI at Baylor is @splon #ASCO15
9:23am May 30th 2015 via Hootsuite
Parsons: Pediatric MATCH - biopsy of recurrent and refractory ped cancers. Can look at freq and spectrum of mutations #ASCO15
9:22am May 30th 2015 via Hootsuite
Parson: For germline WES, cancer pathogenic genes (10% AD). Combining with RNA-Seq data. Real challenge - how to use for clin trials #ASCO15
Parsons: Case:12yo glioneuronal tumor, two somatic mutations, along with germline PTPN11 (Noonans) #ASCO15
9:17am May 30th 2015 via Hootsuite
Parsons: Assessing utility - asking oncologists before and after the tumor WES report. Will report results in June AACR mtg (Utah) #ASCO15
9:16am May 30th 2015 via Hootsuite
Parsons: Tumor WES: 3% established clin utility; 24% potential; 20% 'consensus ca genes'; 53% 'other genes' (ie XIAP, neuroblastoma) #ASCO15
9:15am May 30th 2015 via Hootsuite
Parsons: n=121 tumor WES results charted; CTNNB1, TP53, 14 genes listed. Many genes with only 1 tumor/121 (indicating the problem) #ASCO15
9:14am May 30th 2015 via Hootsuite
Parsons: 'There is huge enthusiasm' from participants. 83% yes, of 17% no, 10% 'overwhelmed'. Scollon ref http://t.co/umSBlZv9PX #ASCO15
9:12am May 30th 2015 via Hootsuite
Parsons: 1ug DNA from frozen tumor, ILMN plus VCrome 2.1 (Baylor NimbleGen platform). 215 pts, >300 parents, 19 oncologists #ASCO15
9:11am May 30th 2015 via Hootsuite
Parsons: Team studying ELSI too. Both oncologists and families are surveyed over time - preferences, learnings. #ASCO15
9:10am May 30th 2015 via Hootsuite
Parsons: Photo of @splon and @hail_cser logo. Emph today: measure impact of ca suscept genes, freq of findings #ASCO15
9:09am May 30th 2015 via Hootsuite
Parsons: BASIC3: Baylor Advancing Seq Into Childhood Ca Care. CLIA WES of matched blood/tumor; germline and somatic mutations #ASCO15
9:08am May 30th 2015 via Hootsuite
Parsons: And challenges of clinical trial design: how to assess utility, small #'s of pts with individual tumor types #ASCO15
9:07am May 30th 2015 via Hootsuite
Parsons: Limited understanding of spectrum of biologically and clinically-relevant mutations; limited models, drugs, experience #ASCO15
9:06am May 30th 2015 via Hootsuite
Parsons: Landscape plot of 1%. and a few 'mountains' of 10%. The reality of many, many mutations in cancer #ASCO15
Parsons:Precision oncology: bringing NGS to the clinic.'13 Nature Gen fig. http://t.co/zhq3WMAQJP MAPK single-pathway. But reality...#ASCO15
9:04am May 30th 2015 via Hootsuite
Donald 'Will' Parsons (Baylor College of Medicine) "Clinical Tumor and Germ-Line Sequencing of Pediatric Malignancies" #ASCO15
9:02am May 30th 2015 via Hootsuite
RT @daniel_kraft: The Race to Build a Real-Life “Star Trek” Medical Tricorder. Can $10M turn a sci-fi into real tech? http://t.co/ho09hxngfC
8:30am May 30th 2015 via Hootsuite in reply to daniel_kraft
RT @CancerResearch: Our immunotherapy focused recap of day 1 of #ASCO15 http://t.co/OgkKiluQmt
7:15am May 30th 2015 via Hootsuite
RT @rlebard: No more #facepalm - one of Apple’s most requested emoji is on its way, and more. http://t.co/mpir7VNjXk http://t.co/tx2L3JFHYX
6:20am May 30th 2015 via Hootsuite in reply to rlebard
RT @StanfordCEHG: Big Data in Biomedicine Conference https://t.co/533nVO8uVY via @stanfordcehg
5:20am May 30th 2015 via Hootsuite in reply to StanfordCEHG
Google's Ingenious Plan to Make Apps Obsolete | WIRED http://t.co/BTbcsr0Dji
10:10pm May 29th 2015 via Hootsuite
Map: How coffee splits the United States in half - The Washington Post http://t.co/3YuJis2B5D
9:30pm May 29th 2015 via Hootsuite
Earthquake expert Lucy Jones live-tweets 'San Andreas' premiere - LA Times http://t.co/qpVvPBfUym As a Los Angeles native, I approve.
8:20pm May 29th 2015 via Hootsuite
McWilliams: They surveyed - almost 80% go beyond single-gene, significant % (50%) uncomfortable w/interpretation of results #ASCO15
6:08pm May 29th 2015 via Hootsuite
Robert McWilliams (Mayo Clinic) "Using the Multidisciplinary Tumor Board to Augment the Value of Cancer Sequencing" #ASCO15
6:06pm May 29th 2015 via Hootsuite
Van Allen: And a crowdsourced variant sharing effort at Tumor Portal http://t.co/mJmKkGu5Ap #ASCO15
6:04pm May 29th 2015 via Hootsuite
Van Allen: Calls out these 'outstanding cancer resources' http://t.co/clIL2Fb6ue http://t.co/8WTJKaZA0a http://t.co/qtNbzOpcH8 #ASCO15
6:02pm May 29th 2015 via Hootsuite
Van Allen: Illustrates the prior cancer genomic report versus newer iterations that are 'human readable' #ASCO15
6:01pm May 29th 2015 via Hootsuite
Van Allen: (PHIAL software homepage at the Broad http://t.co/Op6PRLDjn5 ) #ASCO15
5:58pm May 29th 2015 via Hootsuite
Van Allen: Interpretation - PHIAL '14 Nature Med ref http://t.co/8rJGJ1kkuS applied to 14 pts #ASCO15
5:54pm May 29th 2015 via Hootsuite
Van Allen: Points out role of neoantigen burden ('passengers') that aren't captured in gene panels. #ASCO15
5:51pm May 29th 2015 via Hootsuite
Van Allen: ERCC2 not included in gene panels; this was found using WES. 'Cost approaching equivalence' between WES + panels #ASCO15
Van Allen: Clinical WES - prospectively, Platinum chemotherapy response, found ERCC2 mutations http://t.co/RY0AnWguSt #ASCO15
5:50pm May 29th 2015 via Hootsuite
Van Allen: Overlays the NHGRI sequence cost slide to # of data points for clinical genetics - spiking in '12 #ASCO15
5:48pm May 29th 2015 via Hootsuite
Eliezer Van Allen (Dana Farber) "Informatic Strategies to Turn Sequence Data into Cancer Patient Management" #ASCO15
5:45pm May 29th 2015 via Hootsuite
Ford: Germline cancer panels are here; VUS common; changes approach to genetic counseling. #ASCO15
5:36pm May 29th 2015 via Hootsuite
Ford: Case 3 - unexpected TP53 germline mutation, leading to Li-Fraumeni. Rec'd whole-body MRI, found occult sarcoma in thigh #ASCO15
Ford: Unaffected carriers, didn't recommend prophylactic gastrectomy. Need to understand better the CDH1+ genetic risk. #ASCO15
5:35pm May 29th 2015 via Hootsuite
